Rocket Pharmaceuticals, Inc. (RCKT)
NASDAQ: RCKT · Real-Time Price · USD
13.04
-0.12 (-0.91%)
Nov 20, 2024, 4:00 PM EST - Market closed
Rocket Pharmaceuticals Employees
Rocket Pharmaceuticals had 268 employees as of December 31, 2023. The number of employees increased by 28 or 11.67% compared to the previous year.
Employees
268
Change (1Y)
28
Growth (1Y)
11.67%
Revenue / Employee
n/a
Profits / Employee
-$962,981
Market Cap
1.19B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Pediatrix Medical Group | 5,450 |
Tilray Brands | 2,650 |
Novavax | 1,543 |
Indivior | 1,164 |
Maravai LifeSciences Holdings | 650 |
CareDx | 643 |
Innoviva | 112 |
Mesoblast | 73 |
RCKT News
- 1 day ago - Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst - Benzinga
- 2 days ago - Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference - Business Wire
- 8 days ago - Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association's 2024 Late-Breaking Science Sessions - Business Wire
- 13 days ago - Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference - Business Wire
- 13 days ago - Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress - Business Wire
- 2 months ago - Rocket: Danon Disease Treatment Program Should Carry The Tide Until Regulatory Moves - Seeking Alpha
- 2 months ago - Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease - Business Wire
- 2 months ago - Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors - Business Wire